ABSTRACT
Background: Previous retrospective surveys have shown that lipid management
goals are well achieved in patients with dyslipidemia at relatively low risk for
atherosclerotic diseases. However, more than half of patients in high-risk groups have
not achieved the management goals. Since these surveys, newer medications, including
rosuvastatin and ezetimibe, have emerged in clinical practice that may influence
lipid management